Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making

Overview of attention for article published in Patient preference and adherence, June 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 26 Dimensions

Readers on

mendeley: 42 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 26 publications that cite this research output.

26

The most recent citing publications are shown below. View all 26 publications that cite this research output on Dimensions.

A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis

Article in Rheumatology and Therapy (October 2023)

Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit

Article in Clinical Drug Investigation (June 2022)

Prendre un comprimé ou me faire une injection ? Point de vue des patients quant au choix des traitements de fond (DMARD) dans la polyarthrite rhumatoïde (PR)

Article in Revue du Rhumatisme (October 2021)